A detailed history of Algert Global LLC transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Algert Global LLC holds 430,514 shares of ADPT stock, worth $3.59 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
430,514
Previous 76,323 464.07%
Holding current value
$3.59 Million
Previous $391,000 560.1%
% of portfolio
0.06%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$4.37 - $6.78 $1.55 Million - $2.4 Million
354,191 Added 464.07%
430,514 $2.58 Million
Q3 2024

Nov 12, 2024

BUY
$3.37 - $5.12 $40,440 - $61,440
12,000 Added 18.66%
76,323 $391,000
Q2 2024

Aug 14, 2024

SELL
$2.34 - $3.96 $241,401 - $408,525
-103,163 Reduced 61.59%
64,323 $233,000
Q4 2023

Feb 14, 2024

SELL
$3.46 - $5.33 $543,078 - $836,591
-156,959 Reduced 48.38%
167,486 $821,000
Q3 2023

Nov 13, 2023

BUY
$5.07 - $8.44 $142,974 - $238,008
28,200 Added 9.52%
324,445 $1.77 Million
Q2 2023

Aug 14, 2023

SELL
$6.19 - $8.78 $450,322 - $638,745
-72,750 Reduced 19.72%
296,245 $1.99 Million
Q1 2023

May 12, 2023

BUY
$7.8 - $10.11 $597,776 - $774,810
76,638 Added 26.21%
368,995 $3.26 Million
Q4 2022

Feb 13, 2023

BUY
$6.26 - $9.34 $366,892 - $547,408
58,609 Added 25.07%
292,357 $2.23 Million
Q3 2022

Nov 15, 2022

SELL
$6.5 - $12.67 $375,615 - $732,161
-57,787 Reduced 19.82%
233,748 $1.66 Million
Q2 2022

Aug 15, 2022

BUY
$6.4 - $14.73 $1.16 Million - $2.67 Million
181,559 Added 165.09%
291,535 $2.36 Million
Q1 2022

May 16, 2022

BUY
$10.12 - $28.9 $1.11 Million - $3.18 Million
109,976 New
109,976 $1.53 Million

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $1.19B
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.